Alzamend Neuro, Inc. financial data

Symbol
ALZN on Nasdaq
Location
Atlanta, GA
Fiscal year end
30 April
Latest financial report
11 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 26% % -89%
Return On Equity -181% % -144%
Return On Assets -140% % 4.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,804,741 shares -42%
Common Stock, Shares, Outstanding 3,804,741 shares -34%
Entity Public Float $8,200,000 USD 22%
Common Stock, Value, Issued $380 USD -34%
Weighted Average Number of Shares Outstanding, Basic 3,804,741 shares 522%
Weighted Average Number of Shares Outstanding, Diluted 3,804,741 shares 522%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,645,937 USD 218%
General and Administrative Expense $3,388,963 USD 11%
Operating Income (Loss) $7,034,900 USD -67%
Nonoperating Income (Expense) $6,978 USD 63%
Net Income (Loss) Attributable to Parent $7,041,878 USD -67%
Earnings Per Share, Basic 3.3 USD/shares 67%
Earnings Per Share, Diluted 3.3 USD/shares 67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,713,139 USD -19%
Assets, Current $3,699,282 USD -6.3%
Property, Plant and Equipment, Net $342,551 USD 50%
Assets $4,041,833 USD -3.2%
Accounts Payable, Current $725,851 USD -81%
Liabilities $1,857,328 USD 156%
Retained Earnings (Accumulated Deficit) $64,437,694 USD -12%
Stockholders' Equity Attributable to Parent $2,184,505 USD -37%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $3,968,222 USD
Liabilities and Equity $4,041,833 USD -3.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,362,786 USD -124%
Net Cash Provided by (Used in) Financing Activities $4,035,000 USD 105%
Net Cash Provided by (Used in) Investing Activities $90,000 USD 39%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 3,804,741 shares -34%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,713,139 USD -19%
Deferred Tax Assets, Valuation Allowance $15,247,397 USD -3.3%
Deferred Tax Assets, Gross $15,271,245 USD -3.3%
Depreciation $27,685 USD 118%
Deferred Tax Assets, Operating Loss Carryforwards $10,566,664 USD -2.5%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $66,621,819 USD 9.5%
Share-based Payment Arrangement, Expense $81,277 USD -56%
Interest Expense $6,978 USD -63%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%